


























	 Imidazo[2,1‐b][1,3,4]thiadiazoles	(4a‐g)	were	synthesized	from	3,4,5‐trimethoxy	benzoic	acidand	 thiosemicarbazide.	 Reaction	 of	 4	 with	 Vilsmeier‐Haack	 reagent	 yielded	 imidazo	 [2,1‐
b][1,3,4]	 thiadiazole–5‐carbaldehyde	 derivatives	 (5a‐g).	 Obtained	 imidazo[2,1‐b][1,3,4]
thiadia	 zoles‐5‐carbaldehydes	 were	 subjected	 to	 Knoevenagel	 condensation	 with	 2‐(2,4‐
dioxothia	 zolidin‐3‐yl)acetic	 acid	 (1)	 and	 2‐(4‐oxo‐2‐thioxothiazolidin‐3‐yl)acetic	 (2)	 in	 the
presence	 of	 catalytic	 amount	 of	 piperidine	 and	 acetic	 acid	 to	 afford	 imidazo[2,1‐
b][1,3,4]thiadiazoles	(6a‐g)	and	(7a‐g),	respectively.	The	structures	of	the	newly	synthesized
compounds	 were	 confirmed	 by	 IR,	 NMR	 and	 elemental	 analyses.	 All	 compounds	 were












and	 challenging	 problem	 because	 of	 a	 combination	 factors	
including	 newly	 emerging	 infectious	 diseases	 and	 increasing	
number	 of	 multi‐drug	 resistant	 microbial	 pathogens	 with	
particular	relevance	for	Gram‐positive	bacteria	[1‐5].	In	spite	of	
the	 large	 number	 of	 antibiotics	 and	 chemotherapeutics	
available	 for	 medical	 use,	 the	 emergence	 new	 antibiotic	
resistant	 bacterial	 strains	 in	 the	 last	 decades	 constitutes	 a	
substantial	need	for	new	class	of	antibacterial	agents	[6].	
During	recent	years,	there	have	been	intense	investigations	
on	 thiadiazole	 and	 imidazo	 [2,1‐b][1,3,4]thiadiazole	
compounds,	many	 of	which	 are	 known	 to	 possess	 interesting	
pharmacological	 properties	 such	 as	 anticancer	 [7],	 anti‐
tubercular	 [8],	 antibacterial	 [9],	 antifungal	 [10],	 antimicrobial	
and	 anti‐inflammatory	 [11,12],	 analgesic	 and	 antimicrobial	
[13],	 anticonvulsant,	 analgesic	 [14],	 and	 antisecretory	 [15]	
activities.	 Moreover,	 much	 interest	 has	 also	 been	 focused	 on	
the	cardiotonic	[16],	diuretic	[17]	and	herbicidal	[18]	activities	
displayed	 by	 compounds	 incorporating	 this	 heterocyclic	
system.	
The	 varied	 biological	 activities	 of	 rhodanines	 (2‐thioxo‐
thiazolidin‐4‐one)	and	 their	analogues	have	been	known	 from	
the	 beginning	 of	 the	 20th	 century.	 Rhodanines	 and	 2,4‐thiazo‐
lidinedione	 have	 become	 a	 pharmacologically	 important	 class	
of	 heterocyclic	 compounds	 since	 the	 introduction	 of	 various	
glitazones	and	epalrestat	in	to	clinical	use	for	treatment	of	type	
II	 diabetes	 and	 diabetic	 complications,	 respectively	 [19,20].	
Chemical	 modification	 of	 these	 heterocycles	 has	 constantly	
resulted	 in	 compounds	 with	 broad	 spectrum	 of	 pharma‐
cological	activities.	
2,4‐Thiazolidinedione	 derivatives	 constitute	 an	 important	
class	 of	 heterocyclic	 compounds	 for	 which	 diverse	 biological	
properties	 such	 as	 antibacterial	 and	 antifungal	 [21‐24],	 anti‐
diabetic	 [25],	 cardiotonic	 [26],	 anti‐oedematus	 and	 analgesic	
[27],	cyclooxygenase	and	lipoxygenase	inhibitory	[28]	activities	
have	been	documented	along	past	decades.	




single	 molecular	 frame	 and	 to	 explore	 the	 additive	 effects	
towards	 their	 biological	 activities.	 Hence	 we	 are	 reporting	








Unless	 otherwise	 noted,	 materials	 were	 obtained	 from	
commercial	 suppliers	 and	 used	 without	 further	 purification.	
Melting	points	were	recorded	on	electrothermal	melting	point	
apparatus	 and	 are	 uncorrected.	 Thin	 layer	 chromatography	
(TLC)	 controls	were	 carried	out	 on	precoated	 silica	 gel	 plates	
(F254	Merck).	The	 IR	 spectra	were	 recorded	on	Nicolet	 Impact	
410	 FT‐IR	 spectrophotometer	 using	 KBr	 pellets.	 1H	 and	 13C	
NMR	 spectra	 were	 recorded	 on	 AMX‐400,	 Bruker‐400	 liquid‐
state	NMR	spectrometer	using	 tetramethylsilane	 (TMS)	as	 the	
internal	 standard.	 Chemical	 shifts	 were	 recorded	 as	 	 (ppm).	
Elemental	 analyses	 were	 carried	 out	 using	 a	 Perkin	 Elmer	
2400‐CHN	 Analyzer.	 Spectra	 facilities	 and	 elemental	 analysis	
were	 carried	 out	 by	 Sophisticated	 Analytical	 Instruments	













obtained	 according	 to	 the	procedure	described	by	Al‐Omar	et	
al.	[29]	and	Mazzone	et	al.	[30]	with	a	modification.	A	mixture	
of	 equimolar	 quantities	 of	 3,4,5‐trimethoxy	 benzoic	 acid	 (0.1	
mol),	thiosemicarbazide	(0.1	mol)	and	phosphorus	oxychloride	
(30	 mL)	 was	 refluxed	 gently	 for	 half	 an	 hour.	 After	 cooling,	
water	was	added	(90	mL)	and	the	mixture	was	refluxed	for	4	h	
and	filtered.	The	solution	was	neutralized	by	saturated	solution	
of	 potassium	 hydroxide.	 The	 precipitate	 was	 filtered	 and	
recrystallized	 from	 ethanol.	 Yield:	 80%.	 M.p.:	 205‐208	 °C.	 IR	
(KBr,	 cm‐1):	 3590,	 3117,	 1620.	 1H	 NMR	 (400	 MHz,	 ,	 ppm,	








[2,1‐b][1,3,4]‐thiadiazoles	 were	 obtained	 according	 to	 the	
procedure	described	by	Mazzone	et	al.	[30]	with	a	modification.	
A	 mixture	 of	 equimolar	 quantities	 of	 2‐amino‐5‐(3,4,5‐
trimethoxyphenyl)‐1,3,4‐thiadiazole	 (0.01	 mol)	 and	 an	
appropriate	 α‐bromoketones	 (0.01	 mol)	 was	 refluxed	 in	 dry	
ethanol	 (300	 mL)	 for	 10	 h.	 Excess	 of	 solvent	 was	 removed	
under	 reduced	 pressure	 the	 solid	 hydrobromide	 salts	




thiadiazole	 (4a):	 Yield:	 70%.	M.p.:	 205‐208	 °C.	 IR	 (KBr,	 cm‐1):	
3095,	3033,	2943,	1576,	1490,	1339,	1130,	843.	1H	NMR	(400	
MHz,	 ,	 ppm,	 DMSO‐d6):	 8.75	 (s,	 1H,	 H‐5	 imidazole),	 7.40	 (m,	
5H,	 Ar‐H),	 7.41	 (d,	 2H,	 Ar‐H),	 3.89	 (s,	 6H,	 OCH3),	 3.70	 (s,	 3H,	
OCH3).	
2‐(3,4,5‐trimethoxyphenyl)‐6‐(4‐methylphenyl)‐imidazo[2,1‐
































1H	 NMR	 (400	 MHz,	 ,	 ppm,	 DMSO‐d6):	 8.56	 (s,	 1H,	 H‐5	







Vilsmeier‐Haak	 reagent	 was	 prepared	 by	 adding	
phosphoryl	chloride	(3	mL),	in	dimethylformamide	(20	mL),	at	
0	 °C	with	stirring.	Then	appropriately	substituted	arylimidazo	
[2,1‐b][1,3,4]thiadiazole	 (4a‐g)	 (0.01	 mol)	 was	 added	 to	 the	
reagent	and	stirred	at	0	°C	for	30	min.	The	mixture	was	further	
stirred	for	2h	at	room	temperature	and	at	60	°C	for	additional	2	
h.	 the	 reaction	mixture	was	 then	poured	 in	 sodium	carbonate	
solution	and	stirred	at	90	°C	for	2	h.	After	cooling,	the	mixture	
was	 diluted	 with	 water,	 extracted	 with	 chloroform,	 and	
collective	 extract	 was	 washed	 with	 water	 and	 dried	 over	




thiadiazole‐5‐carbaldehyde	 (5a):	 Yield:	 70%.	 Dark	 brown	





b][1,3,4]thiadiazole‐5‐carbaldehyde	 (5b):	 Yield:	 70%.	
Colourless	 crystals.	 M.p.:	 145‐148	 °C.	 IR	 (KBr,	 cm‐1):	 3089,	
2892,	2765,	1677,	1130,	798.	1H	NMR	(400	MHz,	,	ppm,	DMSO‐




[2,1‐b][1,3,4]thiadiazole‐5‐carbaldehyde	 (5c):	 Yield:	 70%.	
Brownish	product.	M.p.:	155‐157	°C.	IR	(KBr,	cm‐1):	3087,	2940,	
2860,	2798,	1680,	1201,	1167,	823.	1H	NMR	(400	MHz,	,	ppm,	




b][1,3,4]	 thiadiazole‐5‐carbaldehyde	 (5d):	 Yield:	 70%.	
Brownish‐yellow	 crystals.	 M.p.:	 175‐176	 °C.	 IR	 (KBr,	 cm‐1):	
3056,	2976,	2835,	2787,	1674,	1204,	1354,	798.	1H	NMR	(400	




b][1,3,4]	 thiadiazole‐5‐carbaldehyde	 (5e):	 Yield:	 70%.	 Light	





b][1,3,4]	 thiadiazole‐5‐carbaldehyde	 (5f):	 Yield:	 70%.	 Dark	
brown	 crystals.	M.p.:	 176‐178	 °C.	 IR	 (KBr,	 cm‐1):	 3056,	 2894,	
2793,	1673,	1203,	1156,	785.	1H	NMR	(400	MHz,	,	ppm,	DMSO‐
d6):	10.09	 (s,	1H,	CHO),	8.06	 (d,	2H,	Ar‐H),	7.60	 (d,	2H,	Ar‐H),	
7.24	(d,	2H,	Ar‐H),	3.91	(s,	6H,	OCH3),	3.89	(s,	3H,	OCH3).	
6‐(2,5‐dimethoxyphenyl)‐2‐(3,4,5‐trimethoxyphenyl)imidazo	














A	 mixture	 of	 the	 6‐Aryl‐2‐(3,4,5‐trimethoxyphenyl)	
imidazo[2,1‐b][1,3,4]thiadiazole‐5‐carbaldehyde	(5a–g)	 (0.001	
mol),	2‐(2,4‐dioxothiazolidin‐3‐yl)acetic	acid	 [31]	 (0.001	mol),	
piperidine	 (0.001	mol)	 and	 acetic	 acid	 (0.001	mol)	 in	 toluene	








acetic	acid	 (6a):	 Yield:	 77%.	 Light	 yellow	 solid.	M.p.:	 191‐193	
°C.	 IR	 (KBr,	 cm‐1):	3363,	3042,	2953,	1720,	1704,	1660,	1320,	
1156.	 1H	 NMR	 (400	MHz,	 ,	 ppm,	 DMSO‐d6):	 13.65	 (br	 s,	 1H,	
COOH),	7.90	(d,	2H,	Ar‐H),	7.87	(s,	1H,	‐CH=C),	7.48	(m,	5H,	Ar‐
H),	4.69	(s,	2H,	CH2),	3.90	(s,	6H,	OCH3),	3.89	(s,	3H,	OCH3).	13C	
NMR	 (400	 MHz,	 ,	 ppm,	 DMSO‐d6):	 169.45,	 168.23,	 164.12,	
150.65,	149.34,	139.78,	135.82,	133.54,	130.36,	128.48,	127.87,	











DMSO‐d6):	 170.69,	 169.86,	 160.88,	 152.12,	 149.78,	 140.39,	
138.27,	133.86,	133.26,	129.34,	128.74,	126.02,	124.83,	117.53,	






213	 °C.	 IR	 (KBr)	 cm‐1:	 3392,	 3071,	 2955,	 1726,	 1700,	 1670,	
1620,	1340,	1150.	1H	NMR	(400	MHz,	,	ppm,	DMSO‐d6):	13.51	
(br	s,	1H,	COOH),	8.95	(d,	2H,	Ar‐H),	8.15	(m,	2H,	Ar‐H),	7.84	(s,	
1H,	 CH=C),	 7.65	 (m,	 2H,	 Ar‐H),	 4.70	 (s,	 2H,	 CH2),	 3.91	 (s,	 6H,	













3H,	 OCH3),	 3.84	 (s,	 6H,	 OCH3).	 13C	 NMR	 (400	 MHz,	 ,	 ppm,	
DMSO‐d6):	 170.33,	 167.87,	 166.20,	 150.12,	 147.23,	 142.31,	
138.29,	132.11,	131.42,	129.87,	128.65,	124.39,	123.08,	121.78,	





zolidin‐3‐yl)	 acetic	 acid	 (6e):	 Yield:	 59%.	 Yellow	 solid.	 M.p.:	




6H,	 OCH3),	 3.84	 (s,	 3H,	 OCH3).	 13C	 NMR	 (400	 MHz,	 ,	 ppm,	
DMSO‐d6):	 169.37,	 168.26,	 166.02,	 151.73,	 149.91,	 141.27,	
134.87,	132.52,	130.69,	130.12,	129.83,	128.42,	128.12,	125.87,	
120.89,	 112.38,	 59.51,	 45.17,	 43.68.	 Anal.	 Calcd.	 for	





215	 °C.	 IR	 (KBr)	 cm‐1.	 3339,	 3064,	 2896,	 1720,	 1698,	 1660,	
1620,	1334,	1138.	1H	NMR	(400	MHz,	,	ppm,	DMSO‐d6):	13.86	
(br	s,	1H,	COOH),	8.36	(d,	2H,	Ar‐H),	7.98	(s,	1H,	CH=C),	7.91	(d,	
2H,	 Ar‐H),	 7.41	 (d,	 2H,	 Ar‐H),	 4.75	 (s,	 2H,	 CH2),	 3.90	 (s,	 6H,	
OCH3),	3.87	 (s,	3H,	OCH3).	 13C	NMR	(400	MHz,	,	 ppm,	DMSO‐
d6):	 167.73,	 167.07,	 166.57,	 150.37,	 148.25,	 139.19,	 137.34,	
131.48,	130.38,	129.29,	127.96,	125.28,	124.19,	121.17,	120.17,	





















A	 mixture	 of	 the	 6‐Aryl‐2‐(3,4,5‐trimethoxyphenyl)	
imidazo[2,1‐b][1,3,4]thiadiazole‐5‐carbaldehyde	 (5a‐g)	 (0.001	
mol),	2‐(4‐oxo‐2‐thioxothiazolidin‐3‐yl)acetic	acid	(0.001	mol),	
piperidine	 (0.001	mol)	 and	 acetic	 acid	 (0.001	mol)	 in	 toluene	












(s,	 2H,	 CH2),	 3.91	 (s,	 6H,	 OCH3),	 3.88	 (s,	 3H,	 OCH3).	 13C	 NMR	
(400	MHz,	,	 ppm,	DMSO‐d6):	 193.05,	 167.21,	 166.41,	 161.68,	
150.87,	149.30,	139.54,	136.59,	134.12,	131.82,	129.23,	127.92,	
126.61,	 124.83,	 121.32,	 120.41,	 114.32,	 57.31,	 55.58,	 45.19.	






















206‐208	 °C.	 IR	 (KBr,	 cm‐1):	 3392,	 3071,	 2955,	 2868,	 1726,	
1670,	1627,	1324,	1145,	967.	1H	NMR	(400	MHz,	,	ppm,	DMSO‐
d6):	 13.29	 (br	 s,	 1H,	 COOH),	 8.41	 (d,	 2H,	 Ar‐H),	 7.93	 (s,	 1H,	
CH=C),	7.88	(d,	2H,	Ar‐H),	7.80	(d,	2H,	Ar‐H),	4.72	(s,	2H,	CH2),	
3.90	 (s,	 6H,	OCH3),	 3.87	 (s,	 3H,	 OCH3),	 3.71	 (s,	 3H,	 OCH3).	 13C	
NMR	 (400	 MHz,	 ,	 ppm,	 DMSO‐d6):	 193.18,	 167.17,	 166.33,	
159.71,	147.32,	140.86,	137.76,	134.18,	133.62,	130.33,	129.75,	





xothiazolidin‐3‐yl)	 acetic	 acid	 (7d):	 Yield:	 52%.	 Yellow	 solid.	
M.p.:	223‐225	°C.	IR	(KBr)	cm‐1:	3382,	3071,	2934,	2856,	1727,	
1675,	1613,	1323,	1170,	982.	1H	NMR	(400	MHz,	,	ppm,	DMSO‐
d6):	 13.27	 (br	 s,	 1H,	 COOH),	 8.16	 (d,	 2H,	 Ar‐H),	 7.78	 (s,	 1H,	
CH=C),	7.65	(d,	2H,	Ar‐H),	7.34	(d,	2H,	Ar‐H),	4.68	(s,	2H,	CH2),	
3.89	 (s,	 3H,	 OCH3),	 3.87	 (s,	 6H,	 OCH3).	 13C	 NMR	 (400	MHz,	 ,	
ppm,	 DMSO‐d6):	 192.47,	 167.05,	 166.18,	 151.73,	 147.93,	
141.53,	134.20,	133.37,	132.84,	129.20,	127.92,	126.55,	125.43,	






231‐232	 °C.	 IR	 (KBr,	 cm‐1):	 3372,	 3072,	 2947,	 2873,	 1720,	
1678,	1625,	1337,	1129,	978.	1H	NMR	(400	MHz,	,	ppm,	DMSO‐
d6):	 13.22	 (br	 s,	 1H,	 COOH),	 8.14	 (d,	 2H,	 Ar‐H),	 7.70	 (s,	 1H,	
CH=C),	7.25	(d,	2H,	Ar‐H),	6.80	(d,	2H,	Ar‐H),	4.63	(s,	2H,	CH2),	
3.91	 (s,	 3H,	 OCH3),	 3.90	 (s,	 6H,	 OCH3).	 13C	 NMR	 (400	MHz,	 ,	
ppm,	 DMSO‐d6):	 192.75,	 167.02,	 166.26,	 157.93,	 149.32,	
140.73,	136.65,	131.75,	130.33,	129.27,	127.38,	126.11,	123.23,	
117.81,	 117.27,	 109.18,	 57.68,	 45.32,	 43.23.	 Anal.	 Calcd.	 for	









6H,	 OCH3),	 3.89	 (s,	 3H,	 OCH3).	 13C	 NMR	 (400	 MHz,	 ,	 ppm,	
DMSO‐d6):	 192.47,	 167.05,	 166.18,	 150.37,	 147.93,	 139.19,	
137.34,	134.28,	133.23,	132.69,	129.75,	127.28,	126.74,	125.52,	
119.25,	 113.18,	 59.79,	 45.72,	 43.54.	 Anal.	 Calcd.	 for	




thioxothiazolidin‐3‐yl)	 acetic	 acid	 (7g):	 Yield:	 52%.	 Yellow	
solid.	M.p.:	213‐215	°C.	IR	(KBr,	cm‐1):	3373,	3061,	2925,	2845,	
1724,	1681,	1620,	1362,	1134,	968.	1H	NMR	(400	MHz,	,	ppm,	
DMSO‐d6):	13.32	 (br	 s,	1H,	COOH),	8.38	 (d,	2H,	Ar‐H),	7.92	 (s,	














µg/mL	 concentrations	 with	 Mueller‐Hinton	 broth	 and	
Sabouraud	 dextrose	 broth.	 The	 minimum	 inhibitory	
concentrations	(MIC)	were	determined	using	the	twofold	serial	










all	 the	 bacterial	 strains	 after	 24	 h	 of	 incubation	 at	 37	 ±	 1	 °C.	
Fungi	 were	 maintained	 in	 Sabouraud	 dextrose	 broth	 after	





only	 inoculated	 broth	 was	 used	 as	 controls.	 For	 the	
antibacterial	 assay	 after	 incubation	 for	 24	 h	 at	 37±1	 °C	 and	
after	 incubation	 for	48	h	 at	25	±	1°C	 for	 antifungal	 assay,	 the	








The	 synthetic	 route	 of	 the	 compounds	 (6a‐g	 and	7a‐g)	 is	
outlined	 in	 Scheme	 1.	 The	 2‐(2,4‐dioxothiazolidin‐3‐yl)acetic	
acid	 (1)	 was	 prepared	 according	 to	 earlier	 reported	 method	








acid	 and	 thiosemicarbazide	 in	 the	 presence	 of	 phosphorus	
oxychloride,	 the	 latter	 refluxed	 with	 substituted	 α‐haloaryl	






Table1.	Results	of	antibacterial	 and	antifungal	 activities	of	 compounds	 (6a‐g	 and	7a‐g)	 [minimum	 inhibitory	concentration	 (MIC	 in	μg/mL)	values	 (mean	of	
triplicates)]*.	
Compound	 R	 E.c	 P.a S.a E.f C.a C.n	 A.f	 A.n
6a	 H	 128	 128 128 64 64 64	 64	 128
6b	 4‐CH3	 128	 128 128 64 64 64	 128	 128
6c	 4‐OCH3	 128	 128 128 64 64 64	 64	 32
6d	 4‐NO2	 128	 128 128 128 64 64	 64	 128
6e	 4‐Br	 128	 128 16 16 16 16	 16	 32
6f	 4‐Cl	 128	 128 32 32 16 16	 16	 16
6g	 2,5‐(OCH3)	 128	 128 128 128 64 64	 64	 64
7a	 H	 128	 64 64 64 32 32	 16	 16
7b	 4‐CH3	 64	 64 64 64 64 64	 32	 64
7c	 4‐OCH3	 128	 64 64 64 32 64	 32	 64
7d	 4‐NO2	 128	 128 64 64 64 32	 64	 64
7e	 4‐Br	 32	 32 4 8 4 8	 4	 4
7f	 4‐Cl	 64	 32 16 8 8 8	 8	 4
7g	 2,5‐(OCH3)	 64	 64 64 64 32 32	 64	 16
Ampicillin	 ‐	 2	 2 NT NT NT NT	 NT	 NT
Kanamycin	 ‐	 NT	 NT 2 1 NT NT	 NT	 NT



































































Reagents: (a) phosphorus oxychloride; (b) dry ethanol; (c) dimethylformamide, phosphorus oxychloride (Vilsmeiere-Haack reagent); (d) 2-(2,4-dioxothiazolidin-3-yl)acetic acid.  2-(4-






reflux	 temperature	 spontaneously.	 The	 electronic	 and	 steric	
factors	 at	 5th	 position	 of	 2‐amino‐5‐substituted‐1,3,4‐
thiadiazole	are	crucial	in	determining	the	course	of	its	reaction	
with	 substituted	 α‐haloaryl	 ketones.	 The	 strongly	
electronegative	 groups	 impart	 less	 nucleophilic	 character	 to	
the	nitrogen	at	4th	position	of	 the	1,3,4‐thiadiazole.	Various	α‐
haloaryl	 ketones	 were	 prepared	 by	 the	 bromination	 of	 the	
corresponding	ketones.	
Vilsmeier‐Haack	 reaction	 of	 imidazo[2,1‐b][1,3,4]	
thiadiazoles	 (4a‐g)	 in	 dimethylformamide	 and	 phosphorus	
oxychloride	 provided	 6‐aryl‐2‐(3,4,5‐trimethoxyphenyl)	
imidazo[2,1‐b][1,3,4]thiadiazole–5‐carbaldehyde	 derivatives	
(5a‐g).	 Thus	 obtained	 imidazo[2,1‐b][1,3,4]thiadiazoles‐5‐
carbaldehydes	 (5a‐g)	 were	 subjected	 to	 Knoevenagel	
condensation	 with	 2‐(2,4‐dioxothiazolidin‐3‐yl)acetic	 acid	 (1)	
and	 2‐(4‐oxo‐2‐thioxothiazolidin‐3‐yl)acetic	 acid	 (2)	 in	 the	
presence	 of	 catalytic	 amount	 of	 piperidine	 and	 acetic	 acid	 to	
afford	 imidazo[2,1‐b][1,3,4]thiadiazoles	 (6a‐g)	 and	 (7a‐g),	
respectively.	
The	 formation	 of	 2‐aminothiadiazole	 (3)	 by	 the	 reaction	
between	3,4,5‐trimethoxy	 benzoic	 acid	 and	 thiosemicarbazide	
was	 confirmed	 by	 IR	 spectra,	 which	 showed	 the	 presence	 of	
amine	 (–NH2)	 band	 and	 absence	 of	 carbonyl	 stretching	 of	
carboxylic	 acid.	 Structures	 of	 imidazothiadiazole	 derivatives	
(4a‐g)	were	established	by	 the	absence	of	amine	(–NH2)	band	
in	IR	spectra	and	appearance	of	imidazole	proton	(H‐5)	around	
	 8.6	 in	 the	 1H	 NMR	 spectra.	 IR	 spectra	 of	 aldehydes	 (5a‐g)	
displayed	a	sharp	band	for	carbonyl	stretching	frequency	(vC=O)	
around	1680	cm‐1	and	the	signal	for	imidazole	proton	(H‐5)	in	
1H	 NMR	 spectrum	 was	 absent.	 A	 new	 signal	 for	 aldehyde	
proton	 was	 observed	 around	 :	 10.00	 ppm	 in	 the	 1H	 NMR	
spectra,	 thus	 substantiating	 the	 formation	 of	 imidazo[2,1‐
b][1,3,4]thiadiazole‐5‐carbaldehydes.	The	absence	of	 aldehyde	
protons	and	presence	of	 the	methylidene	proton	around		7.7	
















All	 the	 synthesized	 compounds	 exhibited	 varying	 degree	 of	
inhibitory	effect	on	the	growth	of	different	tested	strains	Table	
1.	 Compounds	 6e,	 6f,	 7e	 and	 7f	 showed	 significant	 activity	
against	 S.	 aureus	 and	E.	 faecalis	 and	moderate	 against	E.	 coli,	
P.aeruginosa,	suggesting	that	the	substitution	of	4‐bromopheny	
and	4‐chlorophenyl	groups	might	contribute	to	their	increased	
activities	 while	 4‐methylphenyl,	 4‐methoxylphenyl	 and	 4‐
nitrophenyl	 groups	 at	 6th	 position	 of	 imidazo[2,1‐b][1,3,4]	
thiadiazole	might	 not	 be	 preferable.	Whereas,	 compounds	6a,	
6b,	6c,	6d,	6g,	7a,7b,	7c,7d	and	7g	showed	weak	to	moderate	
activity.	
The	 antifungal	 screening	 of	 all	 compounds	 was	 carried	
against	 four	 fungal	 strains,	 Candida	 albicans	 (ATCC	 2091),	
Aspergillus	 flavus	 (NCIM	 No.	 524),	 Aspergillus	 niger	 (ATCC	
6275),	 and	 Cryptococcus	 neoformans	 (clinical	 isolate).	 All	
synthesized	 compounds	 showed	 significant	 antifungal	 activity	
against	different	fungal	strains.	Although	compounds	7e	and	7f	
showed	 good	 antifungal	 activity	 against	 all	 the	 fungal	 strains,	
compounds	6e	and	6f	also	showed	remarkable	activity	against	
all	 the	 fungal	 strains.	 All	 other	 compounds	 showed	moderate	
activity	against	all	the	fungal	strains	but	compounds	6a,	6b,	6d	
showed	weak	activity	against	A.	niger	and	6b	against	A.	flavus.		
A	 total	 analysis	of	 the	 antibacterial	 and	antifungal	 activity	
revealed	 that	 (i)	 the	2‐((5Z)‐5‐((2‐(3,4,5‐trimethoxyphenyl)‐6‐
arylimidazo[2,1‐b][1,3,4]thiadiazol‐5‐yl)methylene)‐4‐oxo‐2‐
thioxothiazolidin‐3‐yl)	 acetic	 acids	 are	 shown	good	activity	 as	
compare	2‐((5Z)‐5‐((2‐(3,4,5‐trimethoxyphenyl)‐6‐arylimidazo	
[2,1‐b][1,3,4]	 thiadiazol‐5‐yl)methylene)‐2,4‐dioxothiazolidin‐
3‐yl)	 acetic	 acids;	 (ii)	The	antibacterial	 and	antifungal	 activity	
imidazo	 [2,1‐b][1,3,4]thiadiazole	 derivatives	 depended	 upon	
the	 presence	 and	 nature	 of	 the	 substituents,	 which	 were	
introduced	 into	 the	 imidazo[2,1‐b][1,3,4]thiadiazole	 ring.	 (iii)	
The	 antibacterial	 and	 antifungal	 activity	 of	 	 imidazo[2,1‐b]	
[1,3,4]thiadiazole	 derivatives	 were	 enhanced	 by	 the	
introduction	 of	 electron	 withdrawing	 4‐bromophenyl	 and	 4‐





We	 have	 synthesized	 several	 2‐((5Z)‐5‐((2‐(3,4,5‐tri‐
methoxyphenyl)‐6‐arylimidazo[2,1‐b][1,3,4]thiadiazol‐5‐yl)	




activity	 are	 also	 encouraging	 as	 out	 of	 14	 compounds	 tested,	
compounds	6e,	6f,	7e	and	7f	exhibited	antimicrobial	activity.	A	
total	 analysis	 of	 the	 antibacterial	 and	 antifungal	 activity	
revealed	 that	 the	 antibacterial	 and	 antifungal	 activity	 of		
imidazo[2,1‐b][1,3,4]thiadiazole	derivatives	were	enhanced	by	
the	 introduction	 of	 4‐bromopheny	 and	 4‐chlorophenyl	 group	
6th	position	of	imidazo[2,1‐b][1,3,4]thiadiazole	and	the	mode	of	
action	 of	 these	 compounds	 was	 unknown.	 These	 observation	
may	 promote	 a	 further	 development	 of	 this	 group	 of	
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